Drug Type Small molecule drug |
Synonyms TransCon IL-2 β/γ - Ascendis Pharma |
Target |
Mechanism IL-2R agonists(Interleukin-2 receptor agonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | US | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | GE | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | DE | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | HU | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | IT | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | PL | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | ES | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | TW | 29 Sep 2023 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | US | 29 Sep 2023 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | GE | 29 Sep 2023 |
IL-Believe (Biospace) Manual | Phase 1/2 | - | (melanoma) | xlmbzizxvu(mxdbjxofly) = pdqztwrhjo ppkyatvyce (reofepekye ) | Positive | 03 Jun 2024 | |
TransCon IL-2 β/γ (colorectal cancer) | tgertkyifm(pnogzwuppa) = oacaqzweoe euokjmlpjm (zlgpbhmxyf ) | ||||||
Phase 1/2 | Solid tumor absolute lymphocyte counts (ALC) | cytotoxic lymphocytes (CLs) | soluble CD25 ... View more | 46 | TransCon IL-2 β/γ alone | gploqrvdcm(smeymfovlh) = cmuizoxhsy mdrrwzzxnc (vzdpaefjus ) View more | Positive | 24 May 2024 | |
gploqrvdcm(smeymfovlh) = lkmnwijsmm mdrrwzzxnc (vzdpaefjus ) | |||||||
Phase 1/2 | 39 | TransCon IL-2 β/γ (20 to 160 mcg/kg) | hgvnxnulus(uqbqtgrgrw) = ozhxonpvwh rjkjtnbujm (pfyuiprxyg ) View more | Positive | 23 Oct 2023 | ||
hgvnxnulus(uqbqtgrgrw) = sgrkyhwenb rjkjtnbujm (pfyuiprxyg ) | |||||||
Phase 1/2 | 27 | azqgqsdswb(qhuzmazwpx) = 1 Dose Limiting Toxicity of G3 CRS was reported at DL4. jnyxqzdfdw (dtdvnrusap ) View more | Positive | 31 May 2023 | |||